Clinical Trial News

A drug used for Alzheimer's may slow Lewy body dementia progression, according to research from Karolinska Institutet. Cholinesterase inhibitors (ChEIs) like donepezil, rivastigmine, and galantamine, which prevent the breakdown of acetylcholine, showed significant cognitive decline slowing in Lewy body dementia patients compared to memantine. ChEIs also reduced the risk of death within the first year of diagnosis by 34%.

Wegovy (semaglutide) reduces major adverse cardiac events by 28% in heart failure patients, regardless of ejection fraction type, and also lowers heart disease-related and all-cause mortality.

A study involving 39,000 women, including 7,300 with migraines, found no increased risk of Parkinson's disease among those with migraines. Published in the journal *Neurology*, the research suggests no association between migraines and Parkinson's, regardless of migraine frequency or aura presence.

Elinzanetant, a dual NK-1 and 3 receptor antagonist, showed efficacy and safety in Phase III OASIS 1 and 2 studies for treating moderate to severe VMS in menopause, reducing VMS frequency and severity, and improving sleep disturbances and quality of life.

Moderna's updated COVID-19 vaccine targeting KP.2 variant of SARS-CoV-2 has been approved by the U.S. FDA for individuals 12 years and above, with EUA granted for those 6 months through 11 years. The vaccine aims to prevent COVID-19 and is expected to be available soon.

Bayer starts Phase II ALPINE-1 study of BAY3283142, an sGC activator for chronic kidney disease, aiming to provide a new treatment option for cardiovascular diseases.

Explains Phase II drug metabolism, summarizes common enzyme-mediated bioconjugation reactions, and discusses examples of Phase II transformations and their impact on drug pharmacology.

FDA approves Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) for first-line treatment of EGFR-mutated advanced NSCLC, marking a significant development for patients with unmet needs.

Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight, and resulted in sustained weight loss over a three-year treatment period.

FDA issued a Complete Response Letter for Regeneron's linvoseltamab BLA in R/R MM; issue relates to a third-party fill/finish manufacturer. Regeneron working with manufacturer and FDA to resolve and bring linvoseltamab to R/R MM patients. EMA review ongoing. Linvoseltamab is investigational, not yet approved.